Recent Updates
Recently added Catalysts
ELDN Positive Sentiment

eGenesis completa con éxito su segundo xenotrasplante de riñón de cerdo en humanos

Key Takeaway: eGenesis has successfully completed its second xenotransplant of a pig kidney into a human patient. This significant milestone showcases the company's progress in xenotransplantation, which could address the organ shortage crisis. The procedure marks a critical step in developing alternative organ sources for transplantation.
Price reaction · baseline $4.355 (2025-02-11T20:57:00.000Z) · hit during market hours · 4 other ELDN headline(s) in the window, move may be shared
day 0 close · peak
-0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Successful completion of the second pig kidney xenotransplant in humans.
  • Demonstrates advancements in organ transplantation technology.
  • Potential to transform lives through innovative medical solutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+90%
120-day peak, hindsight
Typical move
6.5%
average across 7 past catalysts
Cash runway
~11 mo
Medium dilution risk
Lead asset
AT-1501
Phase 2 · Kidney Transplant Rejection

Full Press Release Details

Transforming Lives. One Organ at a Time.
• Overview Focus Patient Stories Clinical Trials In The News
• Science Mechanism of Action Pipeline Publications & Presentations In The News
• Team Overview Leadership Board of Directors
• Investors Overview News & Events Press Releases Events Publications & Presentations Corporate Governance Governance Overview Committee Composition Ethics Hotline Financials SEC Filings Stock Information Stock Quote & Chart Analyst Coverage Resources Investor FAQs Email Alerts Contact IR
• Culture/Careers Culture Careers
• Contact
• Focus
• Patient Stories
• Clinical Trials
• In The News
• Mechanism of Action
• Pipeline
• Publications & Presentations
• In The News
• Overview
• Leadership
• Board of Directors
• Overview
• News & Events Press Releases Events Publications & Presentations
• Corporate Governance Governance Overview Committee Composition Ethics Hotline
• Financials SEC Filings
• Stock Information Stock Quote & Chart Analyst Coverage
• Resources Investor FAQs Email Alerts Contact IR
• Press Releases
• Events
• Publications & Presentations
• Governance Overview
• Committee Composition
• Ethics Hotline
• SEC Filings
• Stock Quote & Chart
• Analyst Coverage
• Investor FAQs
• Email Alerts
• Contact IR
• Culture
• Careers
• Privacy Overview
• Necessary
• Analytics
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.

Frequently Asked Questions

What is the significance of the xenotransplant?

The xenotransplant represents a major advancement in organ transplantation, potentially addressing organ shortages.

How many xenotransplants has eGenesis completed?

eGenesis has successfully completed two xenotransplants of pig kidneys into human patients.

What does this milestone mean for patients?

This milestone could provide new hope for patients in need of organ transplants.

What type of organ was transplanted?

A pig kidney was transplanted into a human patient during this procedure.

Last updated: Feb 11, 2025